T cell-independent type 2 antigens (TI-2 Ags), such as pneumococcal polysaccharides, elicit weak immunoglobulin G (IgG) responses and are refractive to boosting. Overcoming this challenge is critical for improving vaccines. Previously, we demonstrated a lipid-based adjuvant composed of monophosphoryl lipid A, synthetic cord factor, and squalene significantly boosts primary and secondary IgM and IgG production against polysaccharide Ags. Herein, we show beta-2 microglobulin, but not MHC class II, is essential for adjuvant-induced increases in polysaccharide-specific IgG levels. Furthermore, we demonstrate CD1d expression is essential for optimal adjuvant-induced increases in IgG, but is not required for IgG responses to TI-2 Ags administered without adjuvant, with the exception of the bacterial cell wall polysaccharide component, phosphorylcholine. Adoptive transfer of splenic and peritoneal cells from VHB1-8 transgenic mice into CD1d-/- mice revealed adjuvant-induced increases in NP-Ficoll-specific IgG production by CD1d+/+ transgenic B cells, but not recipient B cells, suggesting B cell-expressed CD1d is critical for adjuvant-induced effects on TI-2 antibody responses. Consistent with this, bone marrow chimera mice with selective CD1d deficiency in B cells demonstrated B cell-expressed CD1d was dispensable for iNKT cell development and maintenance but was required for adjuvant-induced increases in protective levels of polysaccharide- and phosphorylcholine-specific IgG. Notably, both iNKT cells and CD1d crosslinking significantly increased IgG production by B cells coactivated with TI-2 Ag and adjuvant, suggesting iNKT-induced CD1d signaling may promote increased IgG production. In summary, our study reveals B cell-dependent CD1d expression is critical for effectiveness of a potent lipid-based adjuvant in augmenting polysaccharide- and phosphorylcholine-specific IgG responses.
Keywords: B cell; CD1d; adjuvant; antibody; polysaccharide vaccine.
© The Author(s) 2025. Published by Oxford University Press on behalf of The American Association of Immunologists. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.